UNSPSC 51433906: Aprikalim

This classification denotes an antihypertensive agent with the molecular formula C12H16N2OS2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 374BH4KVRG, chemically known as 2h-thiopyran-2-carbothioamide, tetrahydro-n-methyl-2-(3-pyridinyl)-, 1-oxide but generally known as aprikalim, which bears US NIH Compound Identifier 3034038. European Medicines Agency schedules Aprikalim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05541MIG.

UNSPSC 51433906 Aprikalim (Commodity) covers emergency pharmaceutical products that state and local governments procure for fire rescue services, public health programs, and multi-jurisdictional cooperative purchasing initiatives. Recent solicitations show state and local buyers purchasing specific medications—epinephrine injections, labetalol, adenosine, and diltiazem—for Advanced Life Support protocols, as well as engaging in broader generic pharmaceutical procurement through cooperative purchasing vehicles that aggregate demand across multiple states and local entities. The work spans direct medication supply for emergency response, state-level pharmacy benefit program procurement, and multi-state cooperative contracting with manufacturers and wholesalers to deliver pharmaceuticals across public health and human services networks.

Activity centers on fire rescue departments, state health and human services agencies, and cooperative purchasing alliances. The City of Tampa Fire Rescue issued an IFB (Bid No. 26-P-00188, due April 8, 2026) for 370 units of Labetalol, 1,810 units of Epinephrine 1:10,000, 330 units of Adenosine 6mg, and 1,020 units of Diltiazem 25mg, with an estimated contract value of $40,000, including a 5 percent SLBE bid discount not to exceed $10,000. The Texas Health and Human Services Commission posted an RFI (HHS0017013, due April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers to participating state and local facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026. Geographic activity spans Florida, Texas, and the upper Midwest through cooperative purchasing; manufacturers must hold cGMP and DSCSA certification and maintain relationships with authorized wholesalers, with performance penalties ranging from $200 to $1,500 per violation.